Reduced Prevalence of Parkinson’s Disease in Patients Prescribed Calcineurin Inhibitors

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Preclinical evidence suggests calcineurin inhibitors (CNIs) combat α-synuclein-induced neuronal dysfunction and motor impairments. However, whether CNIs prevent or treat Parkinson’s disease (PD) in humans has never been investigated. Objective: We seek to ascertain if prescription of CNIs is linked to a decreased prevalence of PD in a varied patient population and to glimpse into the mechanism(s) and target site through which CNIs might decrease PD prevalence. Methods: We analyzed electronic health records (EHRs) from patients prescribed the brain penetrant CNI tacrolimus (TAC), the peripherally restricted CNI cyclosporine (CySp), or the non-CNI sirolimus (SIR). For comparison, EHRs from a diverse population from the same network served as a general population-like control. After propensity-score matching, prevalence, odds, and hazards of PD diagnoses among these cohorts were compared. Results: Patients prescribed CNIs have decreased odds of PD diagnosis compared to the general population-like control, while patients prescribed SIR do not. Notably, patients prescribed TAC have a decreased prevalence of PD compared to patients prescribed SIR or CySp. Conclusions: Our results suggest CNIs, especially those acting within the brain, may prevent PD. The reduced prevalence of PD in patients prescribed TAC, compared to patients prescribed SIR, suggests that mechanisms of calcineurin inhibition—other than immunosuppression, which is common to both drugs—are driving the reduction. Therefore, CNIs may provide a promising therapeutic approach for PD.

Original languageEnglish (US)
Pages (from-to)533-543
Number of pages11
JournalJournal of Parkinson's Disease
Volume14
Issue number3
DOIs
StatePublished - Apr 23 2024

Keywords

  • Calcineurin
  • Parkinson’s disease
  • TriNetX
  • cyclosporine
  • drug repurposing
  • electronic health records
  • tacrolimus
  • α-synuclein

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Fingerprint

Dive into the research topics of 'Reduced Prevalence of Parkinson’s Disease in Patients Prescribed Calcineurin Inhibitors'. Together they form a unique fingerprint.

Cite this